Rose Ruth Ellison

Cleveland Clinic

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Joseph H. Burchenal

Kettering University

David A. Karnofsky

Kettering University

James F. Holland

Icahn School of Medicine at Mount Sinai

Janet Cuttner

Icahn School of Medicine at Mount Sinai

Richard T. Silver

New York Hospital Queens

Clara D. Bloomfield

The Ohio State University

M. Lois Murphy

Barts Health NHS Trust

Louis A. Leone

University of Augsburg

Ivor Royston

Naval Medical Research Command

Johannes Blom

Karolinska Institutet

Cooperative Institutions

Cornell University

Memorial Sloan Kettering Cancer Center

Kettering University

Harvard University

Dana-Farber Cancer Institute

Roswell Park Comprehensive Cancer Center

Cleveland Clinic

Memorial Hospital

State University of New York

Columbia University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study.

Journal of Clinical Oncology (1988)

Michael Perloff Gerson Lesnick A. E. Korzun Florence C. H. Chu James F. Holland

One hundred thirteen evaluable patients with previously untreated stage III breast carcinoma were treated with three monthly cycles of cyclophosphamide (CYC), doxorubicin (DOX), 5-fluorouracil (5-FU), vincristine (VCR), and prednisone (PRED) (CAFVP). Subsequently, 91 (81%) were deemed operable. Patients were then randomized to receive surgery or radiotherapy (RT) to determine which of these modalities afforded better local tumor control. All patients also received 2 additional years of CAFVP in a further attempt to eradicate local disease and systemic micrometastases. Forty-one of the randomized patients have relapsed. Approximately half of the initial relapses in each arm were local. The overall duration of disease control was similar following either modality, with a median of 29.2 months for surgery patients and 24.4 months for RT patients. Similarly, there was no major difference in survival related to randomized treatment with an overall median of 39 months (median follow-up 37 months). Pre- or perimenopausal status and inflammatory disease were associated with shorter disease control and survival. Treatment was generally well tolerated and toxicity was acceptable. This study demonstrates that prolonged control of stage III breast carcinoma can be achieved with combined modality therapy in which cytotoxic chemotherapy precedes and follows treatment directly primarily at the breast tumor, using either surgery or RT. Nevertheless, new regimens must be designed if significant advances that may lead to the cure of this disease are to be achieved.

Breast carcinoma

10.1200/jco.1988.6.2.261

Cite

Citations (198)

Clinical pharmacological trial of guanazole.

PubMed (1973)

Daniel Yakar James F. Holland Rose Ruth Ellison Arnold I. Freeman

Summary Guanazole was given to 27 patients with advanced neoplastic diseases, mostly acute leukemia, by continuous i.v. infusion in 5-day courses. Toxicity was manifest mainly by myelosuppression, but drug fever, mucositis, rash, and alkalosis were also observed. Complete remission was achieved in two out of 14 patients with previously treated acute myelocytic leukemia, and an M1 marrow occurred in one out of four patients with advanced acute lymphocytic leukemia. Most of the effects of guanazole appear to be dose related, with a narrow therapeutic index. This is the first evidence of therapeutic activity of guanazole in man.

Mucositis

Therapeutic index

Source

Cite

Citations (12)

Clinical evaluation of thioguanosine.

PubMed (1961)

Irwin H. Krakoff Rose Ruth Ellison Charlotte Tan

2-Amino-6-mercapto-9 β -d-ribofuranosylpurine (thioguanosine) has been used orally and intravenously in the treatment of 82 patients with leukemias and disseminated tumors. The oral dose of thioguanosine required to produce toxic or therapeutic responses was less than half the oral dose of thioguanine necessary to produce comparable results calculated on a molar basis. However, the two compounds were equally active when given by the intravenous route, indicating that the difference in oral dosage of the two compounds was due to a difference in absorption. Remissions have occurred in diseases which might have been expected to respond to the purine antagonists (acute leukemia in children and adults and chronic granulocytic leukemia) and only in cases which had not already become resistant to 6-mercaptopurine. Thioguanosine therefore appeared to have no qualitative or quantitative advantages over the previously available purine analogs.

Acute lymphocytic leukemia

Source

Cite

Citations (13)

Effect of the citrovorum factor in pernicious anemia

The American Journal of Medicine (1951)

Rose Ruth Ellison Susan Wolfe Herbert C. Lichtman Victor Ginsberg Janet Watson

pernicious anemia

Intrinsic factor

10.1016/0002-9343(51)90201-x

Cite

Citations (1)

Chromosome studies in acute leukemias developing in patients with multiple myeloma.

PubMed (1975)

Dieter K. Hossfeld James F. Holland Richard G. Cooper Rose Ruth Ellison

Chromosomal findings are reported in three patients with acute myelomonocytic leukemia and in one with reticulosarcoma leukemia who had been treated for multiple myeloma with melphalan and X-ray. All four patients had striking chromosomal anomalies. An iatrogenic causation of aneuploidy is suggested. This is supported by chromosomal findings in patients with acute leukemia following polycythemia vera and Hodgkin's disease; practically all of the leukemias have been aneuploid. A comparison is made of such "secondary" acute leukemias with "primary" acute leukemias that are aneuploid in only 40% of the cases. Chromosomal changes are not considered to be the initial event in leukemogenesis.

Acute myelomonocytic leukemia

Preleukemia

Source

Cite

Citations (38)

Metabolism of Folic Acid and Citrovorum Factor in Leukemic Cells

Elsevier eBooks (1957)

Rose Ruth Ellison Dorris J. Hutchison

Vitamin b complex

10.1016/b978-1-4832-2979-9.50034-6

Cite

Citations (8)

Treating CANCER with Antimetabolites

AJN American Journal of Nursing (1962)

Rose Ruth Ellison

Rose Ruth Ellison, M.D. is an associate member of the Sloan-Kettering Institute for Cancer Research, associate attending physician at Memorial Hospital for Cancer and Allied Diseases, and assistant professor of medicine at Cornell University Medical College, all in New York City. The studies of the author were supported by research grants 61-77-C-5826 and CY-3215 from the National Cancer Institute, United States Public Health Service.

10.1097/00000446-196262110-00014

Cite

Citations (1)

Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group B

Cancer (1980)

Nis I. Nissen Thomas F. Pajak Louis A. Leone Clara D. Bloomfield B. J. Kennedy

The epipodophyllotoxin derivative VP 16–213 (NSC 141540) was studied by the Cancer and Leukemia Group B in a broad phase II trial at three dose levels: 60 mg/m2, 90 mg/m2, and 135 mg/m2 I.V. twice weekly. No correlation between dose of VP 16–213 and response frequency in a particular disease category could be demonstrated. Of the 382 patients, 8% obtained a complete (CR) or partial remission (PR), 8% showed improvement, and 14% had stable disease. By tumor type the best responses were obtained in lymphomas (8/31 CR + PR), uterus (2/9), prostate (1/5), rhabdomyosarcoma (2/6), neuroblastoma (2/4), colon/rectum (5/81), other gastrointestinal (4/32). In lung tumors, 4/80 patients obtained CR or PR. VP 16–213 has definite antineoplastic activity but the response frequency with the twice weekly schedule may be lower than that reported with other schedules.

10.1002/1097-0142(19800115)45:2<232::aid-cncr2820450206>3.0.co;2-f

Cite

Citations (69)

Management of Acute Leukemia in Adults

Medical Clinics of North America (1956)

Rose Ruth Ellison

Myelocytic leukemia

Acute lymphocytic leukemia

Supportive psychotherapy

10.1016/s0025-7125(16)34563-1

Cite

Citations (15)